GoldenGolden
Merck KGaA

Merck KGaA

Merck KGaA is a global science and technology company founded by George W. Merck.

Contents
Timeline
Funding rounds
Products
People
Further reading
Documentaries, videos and podcasts
Companies
News
References

Merck was founded in 1668 by Friedrich Jacob Merck in Darmstadt, Germany.

Merck has almost 53,000 employees in 66 countries. In 2017, they invested a total of € 2.1 billion in research and development.

Merck KGaA, Darmstadt, Germany, holds the rights to the name and the trademark "MERCK" internationally except for the United States and Canada, where they operate in the biopharma market as EMD Serono, in life science as MilliporeSigma, and in the specialty chemicals and high-tech materials business area as EMD Performance Materials.

Timeline

2017

In 2017, Merck KGaA, Darmstadt, Germany, generated sales of €15.3 billion in 66 countries.

People

Name
Role
LinkedIn

Ahmed Khashana

Employee

Alan Edwards

Employee

Alex Mok

Employee

Alexey Malinin

Employee

Amish Patel

Employee

Amparo Rodriguez Cordero

Employee

ANA FERNANDEZ

Employee

Anna Chase

Employee

Anshul Bhatt

Employee

Apoorv Joshi

Employee

Arjun Sikand

Employee

Artem Konopelko

Employee

Ashish Bhatt

Employee

Bernadius Agustinus

Employee

Bianca Harnischfeger

Employee

Binu Varghese

Employee

Bonament Alexi

Employee

Brady Chung, MBA

Employee

Carolina Guthmann

Employee

Chandra Shekhar Karmakar

Employee

Chieh Lin

Employee

Chien-Jung Chiang

Employee

Chirag Satbhaya

Employee

Cristian Lienas

Employee

Dafne Galindo

Employee

Page 1 of 7
12345...7

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Merck prescribes AI for supply chain complexity
Clint Boulton
December 17, 2019
CIO
Pharmaceutical company Merck is using AI to manage an increasingly complex supply chain. Merck CIO Alessandro De Luca explains how its prescriptive supply chain system works.
Versum opens books, begins to warm to rival suitor Merck KGaA
Reuters Editorial
March 29, 2019
U.S.
Versum Materials Inc has opened its books to suitor Merck KGaA, saying the German group's unsolicited $5.9 billion offer might be sweetened and could edge out an agreed merger with Entegris.
Merck KGaA goes hostile in $5.9 billion Versum takeover battle
Ludwig Burger
March 26, 2019
U.S.
German pharma group Merck KGaA on Tuesday sidestepped the management of takeover target Versum Materials and took its $5.9 billion offer directly to the U.S. chemical company's shareholders.
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Merck KGaA
Invalid Date
www.prnewswire.com:443
DARMSTADT, Germany and NEW YORK, Feb. 16, 2019 /PRNewswire/ -- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio ...
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
February 5, 2019
WebWire
, , , , • Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers, , • Merck KGaA, Darmstadt, Germany will receive an upfront payment of €300 million (£260 million) and is eligible for potential development milestone payments of up to €500 million (£440 million) triggered by data from the M7824 lung cancer programme, plus future approval and commercial milestones of up to €2.9 bil...
MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
MilliporeSigma
Invalid Date
www.prnewswire.com:443
- genOway to acquire exclusive rights to MilliporeSigma's foundational genome-editing patents to produce, sell rodent models - New technologies and solutions...
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Merck KGaA
Invalid Date
www.prnewswire.com:443
DARMSTADT, Germany, December 10, 2018 /PRNewswire/ -- The information contained is not intended for distribution in the UK FDA grants M7824, an investigational ...

References

Merck KGaA

merck.de

Categories

Related Topics

Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Product
FeaturesPricingEnterprise
Legal
Terms & ConditionsPrivacy Policy
Help
Help & ResourcesAPI DocumentationContact Us
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.